Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RHOA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RHOA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RHOA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RHOA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RHOA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/RHOA_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RHOA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RHOA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RHOA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RHOA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RHOA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RHOA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001095032 | Oral cavity | NEOLP | positive regulation of endopeptidase activity | 33/2005 | 179/18723 | 1.30e-03 | 9.46e-03 | 33 |
GO:004663412 | Oral cavity | NEOLP | regulation of alpha-beta T cell activation | 22/2005 | 104/18723 | 1.33e-03 | 9.53e-03 | 22 |
GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
GO:0061383 | Oral cavity | NEOLP | trabecula morphogenesis | 12/2005 | 43/18723 | 1.42e-03 | 1.01e-02 | 12 |
GO:003030721 | Oral cavity | NEOLP | positive regulation of cell growth | 31/2005 | 166/18723 | 1.45e-03 | 1.03e-02 | 31 |
GO:005087023 | Oral cavity | NEOLP | positive regulation of T cell activation | 38/2005 | 216/18723 | 1.45e-03 | 1.03e-02 | 38 |
GO:009730532 | Oral cavity | NEOLP | response to alcohol | 43/2005 | 253/18723 | 1.50e-03 | 1.06e-02 | 43 |
GO:007121631 | Oral cavity | NEOLP | cellular response to biotic stimulus | 42/2005 | 246/18723 | 1.55e-03 | 1.09e-02 | 42 |
GO:004663512 | Oral cavity | NEOLP | positive regulation of alpha-beta T cell activation | 16/2005 | 67/18723 | 1.56e-03 | 1.10e-02 | 16 |
GO:001059414 | Oral cavity | NEOLP | regulation of endothelial cell migration | 40/2005 | 232/18723 | 1.64e-03 | 1.14e-02 | 40 |
GO:002176232 | Oral cavity | NEOLP | substantia nigra development | 12/2005 | 44/18723 | 1.76e-03 | 1.21e-02 | 12 |
GO:003112221 | Oral cavity | NEOLP | cytoplasmic microtubule organization | 14/2005 | 56/18723 | 1.89e-03 | 1.28e-02 | 14 |
GO:004353413 | Oral cavity | NEOLP | blood vessel endothelial cell migration | 32/2005 | 176/18723 | 1.93e-03 | 1.30e-02 | 32 |
GO:000751912 | Oral cavity | NEOLP | skeletal muscle tissue development | 29/2005 | 155/18723 | 1.97e-03 | 1.32e-02 | 29 |
GO:190210523 | Oral cavity | NEOLP | regulation of leukocyte differentiation | 46/2005 | 279/18723 | 1.98e-03 | 1.33e-02 | 46 |
GO:003021721 | Oral cavity | NEOLP | T cell differentiation | 43/2005 | 257/18723 | 2.05e-03 | 1.36e-02 | 43 |
GO:00486622 | Oral cavity | NEOLP | negative regulation of smooth muscle cell proliferation | 17/2005 | 75/18723 | 2.08e-03 | 1.38e-02 | 17 |
GO:007121922 | Oral cavity | NEOLP | cellular response to molecule of bacterial origin | 38/2005 | 221/18723 | 2.22e-03 | 1.44e-02 | 38 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:190210721 | Oral cavity | NEOLP | positive regulation of leukocyte differentiation | 29/2005 | 157/18723 | 2.40e-03 | 1.53e-02 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RHOA | SNV | Missense_Mutation | | c.118G>C | p.Glu40Gln | p.E40Q | P61586 | protein_coding | deleterious(0.04) | benign(0.41) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RHOA | SNV | Missense_Mutation | | c.13N>T | p.Arg5Trp | p.R5W | P61586 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-AC-A3TM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
RHOA | SNV | Missense_Mutation | | c.13N>T | p.Arg5Trp | p.R5W | P61586 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
RHOA | SNV | Missense_Mutation | | c.373N>C | p.Glu125Gln | p.E125Q | P61586 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RHOA | SNV | Missense_Mutation | rs11552761 | c.50N>C | p.Gly17Ala | p.G17A | P61586 | protein_coding | deleterious(0) | benign(0.422) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOA | SNV | Missense_Mutation | | c.118N>C | p.Glu40Gln | p.E40Q | P61586 | protein_coding | deleterious(0.04) | benign(0.41) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
RHOA | SNV | Missense_Mutation | rs11552761 | c.50N>A | p.Gly17Glu | p.G17E | P61586 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-GM-A3XG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RHOA | insertion | Frame_Shift_Ins | novel | c.561dupA | p.Ser188IlefsTer30 | p.S188Ifs*30 | P61586 | protein_coding | | | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RHOA | insertion | Nonsense_Mutation | novel | c.165_166insAGCAAACTAGATGAGTTCCAAATGTAA | p.Leu55_Ala56insSerLysLeuAspGluPheGlnMetTer | p.L55_A56insSKLDEFQM* | P61586 | protein_coding | | | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
RHOA | SNV | Missense_Mutation | | c.318N>G | p.Phe106Leu | p.F106L | P61586 | protein_coding | deleterious(0.03) | benign(0.324) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |